SurModics Reports Third Quarter Fiscal 2013 Results
SurModics Reports Third Quarter Fiscal 2013 Results
- Continuing Operations GAAP EPS Increases 22% to $0.22
- $20 Million Share Repurchase Program Authorized
- Revenue and EPS Ranges for Full Year Narrowed
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (NAS: SRDX) , a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced results for its fiscal 2013 third quarter.
Revenue and Earnings Summary
Revenue for the third quarter totaled $14.3 million, a 2% increase from $14.0 million reported in the fiscal 2012 third quarter. Diluted earnings per share from continuing operations totaled $0.22 compared with $0.18 in the prior-year period. Commenting on the results, SurModics' President and Chief Executive Officer, Gary Maharaj, said, "The third quarter was marked by strong earnings. On the revenue side, given the current sluggish medical device industry dynamics, the business performed in-line with our expectations. Although coronary revenues were lower than anticipated, we are encouraged that diversification into other market segments is gaining traction."
For the nine months ended June 30, 2013, revenue totaled $41.8 million, up 10% from $38.1 million in the year earlier period. Diluted earnings per share from continuing operations reached $0.73 versus $0.41 for fiscal 2012.
Medical Device Summary
Revenue for the 2013 third quarter in the Medical Device business unit, which includes hydrophilic coatings and device drug delivery technologies, was $10.6 million, a 3% increase from $10.3 million in the fiscal third quarter of last year. Third quarter hydrophilic coating royalty revenue increased 4% to $7.3 million compared with the year ago period. Medical Device generated $5.2 million of operating income during the quarter, a 1% increase from fiscal 2012. Medical Device operating income was impacted by higher planned research and development expenditures to support the drug coated balloon program.
Additional factors include:
- Two medical device customers launched new products utilizing SurModics hydrophilic coatings;
- Within the segment, neurovascular, peripheral, vascular, structured heart and transcatheter valves all posted growth;
- OrbusNeich's COMBO therapy stent was approved in Europe - this recently launched product incorporates one of SurModics' biodegradable polymer platforms; and
- Coronary sector revenue was weak, down 3%, reflecting headwinds faced by the Company's customer base. SurModics is becoming more diversified, as coronary is declining from the low 40s to the high 30s as a percent of Medical Device hydrophilic coating royalty revenue.
In Vitro Diagnostic Summary
For the third quarter, revenue for the In Vitro Diagnostic (IVD) business unit totaled $3.7 million, up slightly compared with the third quarter of fiscal 2012. The IVD business unit generated $0.9 million of operating income down from $1.1 million in the same quarter of 2012 as a result of higher operating expenses from increased allocation of corporate expenses, as well as additional hiring and market research needed to support growth.
Additional highlights include:
- 11 consecutive quarters of year-over-year revenue growth; and
- The addition of 25 new diagnostic test kit customers.
During the fiscal 2013 third quarter, the Company realized a discontinued operations loss of $47,000, net of tax, from the positive settlement of job incentive obligations with the State of Alabama, offset by a loss from the finalization of prior-year tax liabilities with the filing of the 2012 income tax returns.
As of June 30, 2013, the Company has $60.1 million of cash and investments. SurModics completed its $10.3 million stock repurchase program with the purchase of 299,383 common shares for $7.6 million in the fiscal 2013 third quarter.
Board of Directors Authorizes Stock Repurchase Program
The Company also announced today that its Board of Directors has authorized the repurchase of up to $20 million of its outstanding common stock. Repurchases may be effected through open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, tender offers or by any combination of these methods. The number of shares to be repurchased and the timing of any repurchases will depend on factors such as the Company's stock price, economic and market conditions, the relative attractiveness of corporate development opportunities and other alternative uses of capital, and corporate and regulatory requirements. The share repurchase authorization does not have a fixed expiration date.
Full-Year Revenue and Earnings Outlook
With three quarters of the fiscal year completed, SurModics has narrowed its previously stated fiscal 2013 outlook for revenue and earnings per share from continuing operations. Revenue from continuing operations is expected to be in the range of $55.5 million to $57.0 million. GAAP earnings per share from continuing operations are expected to be in the range of $0.95 to $0.99 per share. The updated earnings per share outlook includes a $0.04 per share fourth quarter 2013 benefit in continuing operations from the finalization of an indemnification agreement signed in July 2013 for reimbursement of historical litigation costs incurred by SurModics in the SRI litigation. Earnings per share for the full year also includes an increase in Research and Development expenses in the fourth quarter of 2013 of at least 20% from the year-ago quarter. The Company's earlier guidance was for revenue in the range of $55.0 million to $58.0 million and GAAP earnings per share from continuing operations in the range of $0.86 to $0.99 per share. Per share information does not take into account any share repurchases that might occur during the balance of fiscal 2013. For fiscal 2012, SurModics reported revenue of $51.9 million and earnings per share from continuing operations of $0.58.
Maharaj concluded, "Going forward, we continue to focus on building SurModics' core business and expanding from that, including a stepped-up R&D initiative. We are pleased that we are on track to achieve higher earnings on solid revenue gains for fiscal 2013."
Correction of Carrying Value of Strategic Investment in Prior Period
As previously disclosed in our second quarter 2013 earnings release, the accompanying financial tables reflect a $1.2 million adjustment to increase the carrying value of our strategic investments, recorded within other assets, and stockholders' equity in the prior period balance sheet. This adjustment corrects and reduces an other than temporary impairment charge as of September 30, 2010, which was previously recorded during the fiscal fourth quarter ended September 30, 2010. The original other than temporary impairment charge did not sufficiently evaluate the impact of the proposed sale of a strategic investment subsidiary to an unrelated third party, in evaluating the value of the strategic investment. This transaction was consummated on February 1, 2011. The impact of this adjustment was not deemed to be material to the results of operations, total assets or stockholders' equity for the previously reported periods. Further details of this adjustment will be included in our Quarterly Report on Form 10-Q for the period ended June 30, 2013.
SurModics will host a webcast at 5 p.m. ET (4 p.m. CT) today to discuss third quarter results. To access the webcast, go to the investor relations portion of the Company's website at www.surmodics.com and click on the webcast icon. A replay of the third quarter conference call will be available by dialing 800-406-7325 and entering conference call ID passcode 4632073. The audio replay will be available beginning at 7 p.m. ET on Wednesday, July 31, 2013, until 7 p.m. ET on Wednesday, August 7, 2013.
About SurModics, Inc.
SurModics' mission is to exceed our customers' expectations and enhance the well-being of patients by providing the world's foremost, innovative surface modification technologies and in vitro diagnostic chemical components. The Company partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit http://www.surmodics.com. The content of SurModics' website is not part of this press release or part of any filings that the Company makes with the SEC.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding our ability to achieve sustainable long-term growth and value creation, our expectations regarding the Company's performance in the near- and long-term, including our revenue and earnings expectations for fiscal 2013, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including (1) reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market and sell products incorporating our technologies may adversely affect our business operations, our ability to realize the full potential of our pipeline, and our ability to achieve our corporate goals; (2) possible adverse market conditions and possible adverse impacts on our cash flows, and (3) the factors identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2012, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at www.surmodics.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.
Use of Non-GAAP Financial Information
In addition to reporting financial results in accordance with generally accepted accounting principles, or GAAP, SurModics is reporting non-GAAP financial results including non-GAAP net income and non-GAAP diluted net income per share. We believe that these non-GAAP measures provide meaningful insight into our operating performance excluding certain event-specific matters, and provide an alternative perspective of our results of operations. We use non-GAAP measures, including those set forth in this release, to assess our operating performance and to determine payout under our executive compensation programs. We believe that presentation of certain non-GAAP measures allows investors to review our results of operations from the same perspective as management and our board of directors and facilitates comparisons of our current results of operations. The method we use to produce non-GAAP results is not in accordance with GAAP and may differ from the methods used by other companies. Non-GAAP results should not be regarded as a substitute for corresponding GAAP measures but instead should be utilized as a supplemental measure of operating performance in evaluating our business. Non-GAAP measures do have limitations in that they do not reflect certain items that may have a material impact upon our reported financial results. As such, these non-GAAP measures presented should be viewed in conjunction with both our financial statements prepared in accordance with GAAP and the reconciliation of the supplemental non-GAAP financial measures to the comparable GAAP results provided for the specific periods presented, which are attached to this release.
|SurModics, Inc. and Subsidiaries|
|Condensed Consolidated Statements of Income|
(in thousands, except per share data)
|Three Months Ended||Nine Months Ended|
|June 30,||June 30,|
|Royalties and license fees||$||7,827||$||7,104||$||22,294||$||19,997|
|Research and development||885||1,107||2,853||2,639|
|Operating costs and expenses|
|Research and development||4,009||3,503||11,145||10,653|
|Selling, general and administrative||4,052||3,412||11,552||10,272|
|Total operating costs and expenses||10,051||9,166||28,591||26,381|
|Operating income from continuing operations||4,238||4,793||13,244||11,704|
|Impairment loss on investments||
|Other income (loss), net||62||139||1,518||(214||)|
|Income from continuing operations before income taxes||4,300||4,932||14,762||11,490|
|Income tax provision||(1,122||)||(1,758||)||(3,916||)||(4,215||)|
|Income from continuing operations||3,178||3,174||10,846||7,275|
|(Loss) income from discontinued operations, net of taxes||(47||)||(30||)||635||1,231|
|Loss on sale of discontinued operations, net of taxes||
|(Loss) income from discontinued operations||(47||)||(112||)||635||216|
|Basic income (loss) per share:|
|Diluted income (loss) per share:|
|Weighted average number of shares outstanding:|
|SurModics, Inc. and Subsidiaries|
|Condensed Consolidated Balance Sheets|
|Cash and short term investments||$||28,434||$||29,657|
|Other current assets||1,908||822|
|Current assets of discontinued operations||45||883|
|Total current assets||38,333||39,955|
|Property and equipment, net||12,870||13,610|
|Liabilities and Stockholders' Equity|
|Current liabilities of discontinued operations||125||1,640|
|Total current liabilities||3,799||6,899|
|Total stockholders' equity||98,039||94,988|
|Total liabilities and stockholders' equity||$||103,926||$||104,319|
|SurModics, Inc. and Subsidiaries|
|Condensed Consolidated Statements of Cash Flows|
|Nine Months Ended|
|Income from discontinued operations||(635||)||(1,231||)|
|Loss on sale of discontinued operations||
|Depreciation and amortization||2,174||2,214|
|Gain on sale of available-for-sale securities and strategic investments||(1,460||)||(172||)|
|Net other operating activities||415||335|
|Change in operating assets and liabilities:|